Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era

被引：29

作者：

Bedimo R. ^{[1
]}

机构：

[1] VA North Texas Health Care System, University of Texas, Southwestern Medical Center, Dallas, TX 75216

来源：

Current HIV/AIDS Reports | 2008年 / 5卷 / 3期

关键词：

Anal Cancer; Cancer Risk Association;

D O I：

10.1007/s11904-008-0022-4

中图分类号：

学科分类号：

摘要：

In the highly active antiretroviral therapy (HAART) era, the incidence of AIDS-defining malignancies (ADMs) has declined significantly. On the other hand, the incidence of other malignancies not known to be associated with immunosuppression (non-ADMs) has not changed and remains significantly higher than in the general population. Some recent controlled studies even suggest that the incidence of selected non-ADMs has increased in the HAART era. These trends warrant a high index of suspicion for malignancies among HIV care providers and a renewed focus on understanding the mechanisms underlying the increased rates. Potential explanations for the higher non-ADM rates include longer survival of patients with HIV on HAART, with only partial immune recovery achieved in most patients; high incidence of human papillomavirus, Epstein-Barr virus, and hepatitis C virus coinfection in patients with HIV infection; and potential oncogenicity of long-term HIV infection or of long-term HAART. Copyright © 2008 by Current Medicine Group LLC.

引用

页码：140 / 149

页数：9

共 53 条

[1]

Mocroft A., Brettle R., Kirk O., Et al., Changes in the cause of death among HIV positive subjects across Europe: Results from the EuroSIDA study, AIDS, 16, pp. 1663-1671, (2002)

[2]

Palella Jr F.J., Delaney K.M., Moorman A.C., Et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators, N Engl J Med, 338, pp. 853-860, (1998)

[3]

Sackoff J.E., Hanna D.B., Pfeiffer M.R., Torian L.V., Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City, Ann Intern Med, 145, pp. 397-406, (2006)

[4]

Palella Jr F.J., Baker R.K., Moorman A.C., Et al., Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study, J Acquir Immune Defic Syndr, 43, pp. 27-34, (2006)

[5]

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults, J Natl Cancer Inst, 92, pp. 1823-1830, (2000)

[6]

Clifford G.M., Polesel J., Rickenbach M., Et al., Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy, J Natl Cancer Inst, 97, pp. 425-432, (2005)

[7]

Mbulaiteye S.M., Biggar R.J., Goedert J.J., Engels E.A., Immune deficiency and risk for malignancy among persons with AIDS, J Acquir Immune Defic Syndr, 32, pp. 527-533, (2003)

[8]

Herida M., Mary-Krause M., Kaphan R., Et al., Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients, J Clin Oncol, 21, pp. 3447-3453, (2003)

[9]

Frisch M., Biggar R.J., Engels E.A., Goedert J.J., Association of cancer with AIDS-related immunosuppression in adults, JAMA, 285, pp. 1736-1745, (2001)

[10]

Engels E.A., Brock M.V., Chen J., Et al., Elevated incidence of lung cancer among HIV-infected individuals, J Clin Oncol, 24, pp. 1383-1388, (2006)

← 1 2 3 4 5 6 →